Interestingly, nerve growth factor (NGF) in combination with GRK2 promotes opioid receptors phosphorylation whilst amplifying the pain, and when treated with anti-NGF therapies, there was significant relief in cancer bone pain by mediating the outcome of GRK2 and arrestins. Here, GRK2 is linked to cancer.